Back to top

cell-therapy: Archive

Zacks Equity Research

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

BIIBNegative Net Change VRTXPositive Net Change FOLDPositive Net Change CRSPPositive Net Change

Zacks Equity Research

CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?

On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.

REGNPositive Net Change PFENegative Net Change VRTXPositive Net Change CRSPPositive Net Change

Zacks Equity Research

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.

BMYPositive Net Change PRMEPositive Net Change KRYSPositive Net Change FULCPositive Net Change

Zacks Equity Research

TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study

2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.

REGNPositive Net Change BMYPositive Net Change NVOPositive Net Change